Gevorg Yaghjyan/LinkedIn
May 20, 2026, 14:13
Gevorg Yaghjyan: Targeting Myostatin in Clinical Trials to Preserve Muscle During Weight Loss
Gevorg Yaghjyan, Project Leader at Parexel, shared a post on LinkedIn:
“Obesity drugmakers chase weight loss. Biohaven is betting on muscles.
GLP-1s deliver weight loss, but trials keep showing a catch: approximately 25-40% of that loss can be lean muscle mass.
Biohaven’s approach: target myostatin in clinical trials to preserve muscle during weight loss.
The hypothesis — better body composition, not just lower weight, drives long-term outcomes.If the data holds, the next obesity trial endpoint might not be pounds lost. It might be muscle retained.
The weight loss race is crowded. The muscle preservation lane is wide open.”
Other posts featuring Gevorg Yaghjyan on Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia